Following years of inadequate supply, a recently approved recombinant Bacillus Calmette-Guérin (rBCG) is now available in the United States to treat non-muscle invasive bladder cancer (NMIBC) patients.
Access to this vaccine may end the multi-year shortage of the TICE® BCG vaccine.
Read More
